{"id":"NCT02300220","sponsor":"Imperial College London","briefTitle":"Targeted Retreatment of COPD Exacerbations","officialTitle":"Targeted Retreatment of Incompletely Recovered COPD Exacerbations With Ciprofloxacin: a Double-blind, Randomised, Placebo-controlled, Multicentre Phase III Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-05","primaryCompletion":"2019-01-22","completion":"2019-01-22","firstPosted":"2014-11-24","resultsPosted":"2021-03-08","lastUpdate":"2021-03-08"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Ciprofloxacin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ciprofloxacin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.","primaryOutcome":{"measure":"Time to the Next COPD Exacerbation","timeFrame":"Up to 90 days","effectByArm":[{"arm":"Ciprofloxacin","deltaMin":72,"sd":null},{"arm":"Placebo","deltaMin":58,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.764"}]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United Kingdom"]},"refs":{"pmids":["32267724"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":72},"commonTop":["Diarrhoea","Abdominal Colic/Pain","Nausea","Pruritis/Rash","Ankle Pain/Tendonitis"]}}